Erasca’s RAS-Targeting Pill Shrinks Tumors in 40% of Advanced Pancreatic Cancer Patients, 62% in Lung Cancer Cases
Erasca’s experimental pan-RAS pill shrank tumors in 40% of advanced pancreatic and 62% of non-small cell lung cancer patients in trials.




